Kodiak SciencesKOD
Recorded

Kodiak Sciences UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration32 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Michael YeeSenior Biotechnology Analyst and Global Head of Biotech Research

All right. Well, good morning, everyone. Thank you very much for joining us on our next session. I am Michael Yee, Senior Biotechnology Analyst and Global Head of Biotech Research here at UBS, and very pleased to have the Chief Executive Officer of Kodiak Sciences, Mr. Victor Perlroth, up here with us. Thank you so much. Great to see you, Victor.

Victor PerlrothCEO

Thanks, Mike. Good to be here.

Michael YeeSenior Biotechnology Analyst and Global Head of Biotech Research

It has been an exciting year for you. I think your stock is up massively this year, as you have put up a lot of positive data earlier this year and then recently too. Lots of phase III data, very de-risked, very exciting time. If all that was not enough, there is a second drug we are going to get data on too. Let us unpack that a little bit. Maybe you could just give us a brief introduction to Kodiak from the standpoint of what your lead drug is and the value proposition of tarcocimab, and walk through what the profile of that drug looks like, particularly against what everybody knows here in Europe and abroad from Roche and Regeneron with high-dose EYLEA. Talk a little bit about your drug and what was so exciting about the results.

Victor PerlrothCEO

Yeah. Thanks, Michael. Well, the journey of the anti-VEGF class obviously goes back more than 20 years. Since that time with Lucentis and EYLEA, with the monthly dosing or the every other month dosing, the journey has been about, well, how do we get that efficacy? How do we get that immediacy? At the same time, how do we get a better durability so that we can give fewer doses over time? That has been a holy grail in the sector. 20 years later, starting in maybe 2004, 2005, 2006, nobody was able to do that.

Victor PerlrothCEO

People began to think, "Well, maybe a biologic can't do that, so maybe you need to have something more exotic like a gene therapy or some sort of drug delivery port or some system." We began the journey a number of years ago to try to solve that problem, and it's a very difficult problem. We developed our ABCs or our antibody conjugate technology, and then we've been testing that with tarcocimab in different ways. The framework that I like to think about is this sort of four-quadrant plot where you have the efficacy, immediacy on the Y-axis and the durability on the X. Where you want to be is that upper right quadrant where you have the same efficacy, immediacy as EYLEA and Lucentis, let's say, and you want to have a definitively different kind of durability.

Victor PerlrothCEO

I think when we went into the DAYBREAK study, and we didn't know, well, what could we show, right? We needed to have that efficacy and immediacy of the Lucentis or EYLEA, and we wanted to try to have a better durability. Obviously in the field, Roche did their best attempt, and with Lucentis, then they were able to develop Vabysmo, which didn't really deliver on the scientific concept of the bispecific mechanism with the Ang-2.

Victor PerlrothCEO

The label, I think, says, "No clinical benefit of Ang-2 was shown." Perhaps it did show some incremental durability, or maybe from a variety of different perspectives, it had maybe incrementally better from a variety of perspectives than, say, EYLEA. Regeneron's attempt to solve the problem, to try to get into that upper right quadrant, was to develop higher-dose EYLEA HD. It, again, is fairly incremental vis-à-vis EYLEA. Vabysmo and EYLEA, we kind of term them as Gen 1.5 agents, and they're just definitively not in that upper right quadrant. Going into DAYBREAK, which was, I think, a study design where we brought a lot of conservatism in terms of the study, but also some new ideas about how we should design the study.

Victor PerlrothCEO

We didn't know before the readout, and running these phase III studies in treatment-naive wet AMD against EYLEA, which is a strong comparator, it's very hard to see what's really happening in the study. I think we were quite measured in advance of the readout.

Victor PerlrothCEO

And we're saying, "Well, maybe we could be a little bit more incrementally better than HD and Vabysmo. Maybe our immediacy could be a little weaker maybe than EYLEA, and that still would be good. Maybe we could be on the edge of the upper right quadrant. Maybe that would be very good." And I think obviously we were very surprised.

Michael YeeSenior Biotechnology Analyst and Global Head of Biotech Research

I mean You were in the upper right-hand quadrant.

Michael YeeSenior Biotechnology Analyst and Global Head of Biotech Research

Yeah, we're So, yeah. So, basically, to summarize for investors, if you haven't taken a look at this data, you basically showed the immediacy right on top of the curves of EYLEA.

Michael YeeSenior Biotechnology Analyst and Global Head of Biotech Research

Tell us about your durability.

Victor PerlrothCEO

Yeah. The immediacy is either the same or maybe better, both in terms of the OCT and the fluid control, and also the powerful vision coming out of your starting point. At the same time, we did four loading doses, and coming out of that, we brought essentially, initially 48% of the patients to six-month dosing, and through the endpoint, more than half the patients. There is a lot of, I wouldn't really call it trickery, but a lot of different approaches that sponsors take to try to push durability in different ways. It is important when you interpret studies from Regeneron with HD or Roche with Vabysmo to understand, well, how they define durability in the study. We decided because with tarcocimab, let's not use any gimmicks. Let's try to use retreatment approaches that are as close to what the physicians do in their practice.

Victor PerlrothCEO

What the physician does is they take the OCT image of the fluid of the eye, and they just kind of print it out and put it next to the patient. A photographer does that, and then the physician comes in, and then they look, and if they see any fluid there, they are going to treat the patient.

Victor PerlrothCEO

Right. We established a methodology to do that, whether it is AI or whatever you want to call it.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day